Federal Agencies Prepare to Restrict High-Concentration 7-OH Kratom Products
New rules targeting semi-synthetic compounds could take effect as early as this Friday, following years of public debate and a recent shift in federal policy.
By Lorenzo Marshall ·

The U.S. Department of Health and Human Services and the Drug Enforcement Administration have finalized a plan to restrict specific 7-OH kratom products, with the new rules potentially taking effect on Nov. 13, 2026. The regulation targets items with higher concentrations of 7-hydroxymitragynine and mitragynine pseudoindoxyl, while leaving traditional botanical kratom largely untouched.
7-OH is a major psychoactive ingredient found in the leaves of the kratom tree, which belongs to the coffee family. While naturally present in small amounts, 7-OH acts more like an opioid in the human brain than the whole leaf. In recent years, concentrated forms of this compound have appeared in smoke shops, liquor stores, and gas stations, sold as tablets, gummies, and tonics.
The federal government’s approach has shifted over the past few months. In August, the DEA initially restricted three semi-synthetic opioids derived from 7-OH, including MGM-15, MGM-16, and MGPI, placing them in the same category as heroin and LSD. This move prompted the American Kratom Association to file a federal lawsuit on Aug. 26, arguing that the rule would unfairly affect natural kratom products containing trace amounts of MGPI.
Following that backlash, HHS issued a new recommendation on Oct. 9, prompting the DEA to narrow its focus. The agency now intends to regulate only products with higher concentrations of 7-OH and MGPI. Officials state that natural kratom products are not the primary target of the new restrictions.
Researchers and policy officials note that 7-OH users often display classic signs of addiction. David Epstein, a senior investigator at the National Institute on Drug Abuse, said his ongoing research suggests the risk of dependence is higher with 7-OH products than with whole leaf kratom. He described cases where users felt well for a few days but then required daily doses to avoid withdrawal, with some needing to take medication in the middle of the night to stay functional.
Estimates for kratom use in the U.S. vary widely. Some data suggests over 5 million people have used kratom in their lifetime, while Epstein has seen estimates as high as 15 million. These figures do not always distinguish between whole leaf products and concentrated 7-OH derivatives.
A recent report analyzing data from 53 U.S. poison control centers found that calls related to kratom increased by roughly 1,200% between 2015 and 2025. The report, authored in part by Chris Holstege, a professor of emergency medicine at the University of Virginia, noted 233 associated deaths during that period. Seventy-nine percent of those deaths involved multiple substances, including opioids and stimulants. However, Holstege noted that 62% of the reports involved people using kratom without other drugs.
Users of the products report mixed experiences. Angela Wilson, 44, of Delaware, said she has taken 32 to 40 milligrams of 7-OH daily for a year and a half to manage chronic pain and depression. She described the substance as life-changing and warned that losing access would be devastating for her family. In contrast, Tyler, 38, who used 7-OH to ease opioid withdrawal in 2025, reported taking 300 to 400 milligrams daily. He entered a rapid detox program in Michigan in March 2026 after finding it difficult to stop without medical support.
Brian, 41, said he spent about $150 a day on 1,200 milligrams of 7-OH at the height of his use. He stopped taking the substance in April 2026, citing debilitating withdrawals that included anxiety, gastrointestinal issues, and a lack of desire to leave his home. He noted that the withdrawal symptoms were more severe than those he experienced when quitting opioids in 2016.
The NIDA website states that early studies suggest kratom and its compounds warrant further research as experimental treatments for substance use disorders. Holstege said he has a growing list of patients in addiction clinics who are managing 7-OH withdrawal. He questioned the current marketing of these products, noting that many shops near his campus appear to target a broad audience rather than just those with opioid dependencies.






